相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC
Paola Bordi et al.
LUNG CANCER (2019)
Are liquid biopsies a surrogate for tissue EGFR testing?
J. W. Goldman et al.
ANNALS OF ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Development and Clinical Utility of a Blood-Based Test Service for the Rapid Identification of Actionable Mutations in Non-Small Cell Lung Carcinoma
Hestia Mellert et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib
Suzanne Jenkins et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer
Suzanne Jenkins et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Catherine Labbe et al.
LUNG CANCER (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients
Yuebi Hu et al.
CLINICAL CANCER RESEARCH (2017)
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291
Kenneth S. Thress et al.
LUNG CANCER (2015)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
分享论文
